Bio-Path Holdings, Inc. (BPTH) Income Statement Analysis

See more : The Limestone Boat Company Limited (BOAT.V) Income Statement Analysis – Financial Results

Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Bio-Path Holdings, Inc. (BPTH)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.biopathholdings.com

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	37.00K	13.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.44K	43.81K	59.45K	79.31K
Cost of Revenue	178.00K	178.00K	161.00K	151.00K	230.00K	426.00K	0.00	0.00	201.76K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.11K	37.77K	43.88K	55.42K
Gross Profit	-178.00K	-178.00K	-161.00K	-151.00K	-230.00K	-426.00K	37.00K	13.00K	-201.76K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.67K	6.05K	15.58K	23.90K
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-9.05%	13.80%	26.20%	30.13%
Research & Development	11.61M	9.17M	5.91M	6.58M	4.59M	4.60M	5.48M	5.47M	3.02M	1.83M	1.63M	1.60M	1.14M	1.14M	480.26K	333.47K	0.00	0.00	0.00	0.00
General & Administrative	4.11M	4.74M	4.53M	4.33M	4.11M	3.38M	3.52M	3.01M	2.46M	2.72M	1.63M	986.10K	0.00	704.88K	1.31M	587.16K	0.00	0.00	0.00	0.00
Selling & Marketing	123.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	4.24M	4.74M	4.53M	4.33M	4.11M	3.38M	3.52M	3.01M	2.46M	2.72M	1.63M	986.10K	1.22M	704.88K	1.31M	587.16K	107.44K	141.31K	82.53K	78.16K
Other Expenses	0.00	0.00	0.00	0.00	0.00	608.00K	0.00	0.00	196.66K	0.00	0.00	0.00	0.00	0.00	182.98K	171.95K	0.00	0.00	0.00	0.00
Operating Expenses	15.84M	13.90M	10.44M	10.91M	8.69M	7.98M	9.00M	8.49M	5.48M	4.54M	3.27M	2.58M	2.37M	1.85M	1.97M	1.09M	107.44K	141.31K	82.53K	78.16K
Cost & Expenses	15.84M	13.90M	10.44M	10.91M	8.69M	7.98M	9.00M	8.49M	5.48M	4.54M	3.27M	2.58M	2.37M	1.85M	1.97M	1.09M	127.55K	179.08K	126.40K	133.58K
Interest Income	36.00K	33.00K	3.00K	26.00K	94.00K	7.00K	9.00K	12.00K	17.67K	22.63K	4.04K	779.00	2.91K	1.30K	3.38K	41.06K	0.00	541.00	132.00	1.35K
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.94K	13.08K	17.62K	13.26K
Depreciation & Amortization	82.00K	178.00K	161.00K	151.00K	230.00K	426.00K	411.00K	204.00K	201.76K	170.91K	160.63K	185.27K	211.71K	197.27K	182.98K	171.95K	1.68K	2.72K	3.03K	3.06K
EBITDA	-15.76M	-13.69M	-10.28M	-10.73M	-8.37M	-8.16M	-8.56M	-8.27M	-5.27M	-4.35M	-3.11M	-2.40M	-2.15M	-1.88M	-1.79M	-2.68M	-107.44K	-132.00K	-63.79K	-49.85K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-28,348.65%	-76,800.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-973.44%	-301.30%	-107.30%	-62.85%
Operating Income	-15.84M	-13.90M	-10.44M	-10.91M	-8.69M	-8.59M	-8.97M	-8.48M	-5.48M	-4.54M	-3.27M	-2.58M	-2.37M	-2.33M	-1.97M	-2.89M	-109.11K	-135.27K	-66.95K	-54.26K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-24,232.43%	-65,192.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-591.78%	-308.75%	-112.61%	-68.42%
Total Other Income/Expenses	-235.00K	33.00K	3.00K	26.00K	94.00K	7.00K	1.94M	1.73M	18.21K	22.05K	3.23K	-344.86K	2.27K	-232.43K	3.38K	41.06K	56.67K	-12.54K	-17.49K	-11.91K
Income Before Tax	-16.08M	-13.87M	-10.44M	-10.88M	-8.60M	-8.58M	-7.02M	-6.75M	-5.47M	-4.52M	-3.27M	-2.58M	-2.36M	-2.08M	-1.97M	-2.85M	-52.45K	-147.81K	-84.44K	-66.17K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-18,981.08%	-51,923.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-284.44%	-337.37%	-142.02%	-83.43%
Income Tax Expense	0.00	-33.00K	-3.00K	-26.00K	-94.00K	-608.00K	-1.94M	-1.73M	0.00	-22.30K	-3.23K	-142.00	-2.27K	232.43K	0.00	2.85M	100.00	100.00	100.00	100.00
Net Income	-16.08M	-13.84M	-10.44M	-10.86M	-8.51M	-8.58M	-7.02M	-6.75M	-5.47M	-4.52M	-3.27M	-2.58M	-2.36M	-2.08M	-1.97M	-2.85M	-52.55K	-147.91K	-84.54K	-66.27K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-18,981.08%	-51,923.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-284.99%	-337.60%	-142.19%	-83.56%
EPS	-33.64	-38.03	-31.04	-56.44	-64.02	-287.54	-278.69	-291.26	-243.61	-202.50	-183.04	-174.15	-175.57	-172.91	-186.06	-277.22	-3.84	-14.13	-13.71	-10.75
EPS Diluted	-33.64	-38.03	-31.04	-56.44	-64.02	-287.54	-278.69	-291.26	-243.61	-202.50	-183.04	-174.15	-175.57	-172.91	-186.06	-277.22	-3.84	-14.13	-13.71	-10.75
Weighted Avg Shares Out	478.00K	363.80K	336.25K	192.35K	132.85K	29.85K	25.20K	23.18K	22.44K	22.32K	17.84K	14.83K	13.46K	12.04K	10.59K	10.29K	13.69K	10.47K	6.17K	6.17K
Weighted Avg Shares Out (Dil)	478.00K	363.80K	336.25K	192.35K	132.85K	29.85K	25.20K	23.18K	22.44K	22.32K	17.84K	14.83K	13.46K	12.04K	10.59K	10.29K	13.69K	10.47K	6.17K	6.17K

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2021 Results - Earnings Call Transcript

May 14, 2021seekingalpha.com

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2021 Results - Earnings Call Transcript

Bio-Path Holdings Reports First Quarter 2021 Financial Results

May 14, 2021globenewswire.com

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

May 7, 2021globenewswire.com

HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

April 5, 2021benzinga.com

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejection: Acadia said the FDA has issued a complete response letter...

Bio-Path Stock Price Increased Over 15% Pre-Market: Why It Happened

April 5, 2021pulse2.com

The stock price of Bio-Path Holdings Inc (NASDAQ: BPTH) has increased by over 15% pre-market. This is why it happened.

Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study

April 5, 2021benzinga.com

Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapies, decitabine and venetoclax. The safety run-in comprised six evaluable patients.

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

April 5, 2021globenewswire.com

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the safety...

Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade

March 16, 2021zacks.com

Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

March 11, 2021globenewswire.com

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster...